Rockridge Resources Appoints Jonathan Wiesblatt as a Strategic Advisor
VANCOUVER, British Columbia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd.(TSX-V: ROCK)(OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge”) (the “Company”) is pleased to announce that Jonathan Wiesblatt has joined the Company as a Strategic Advisor to assist Rockridge’s management team with its capital markets and corporate strategy going forward.
Mr. Wiesblatt has over two decades of experience in the financial industry in various roles including focused expertise in the mining industry as an analyst and institutional investor. Mr. Wiesblatt specializes in equity research, portfolio management, capital markets, hedge funds, and investment management. His expertise in US and Canadian capital markets will be invaluable to the company as Rockridge endeavours to create shareholder value through new mineral discoveries and the advancement of projects in geopolitically favourable jurisdictions. Mr. Wiesblatt has spent the last 15-years as an institutional investor working as a Portfolio Manager for several multi-strategy funds, a Canadian Equity Mutual Fund at Sprott Asset Management, as well as recently serving as an advisor to one of Canada’s largest Family Offices, Reichmann International Development Corp. He is a graduate of The University of Western Ontario and Chartered Investment Manager Designation holder.
"We are thrilled have Jon join the Rockridge team as he brings strong managerial and capital markets expertise to our advisory board," said Jordan Trimble, President of Rockridge Resources. "He has had a very impressive career in the Canadian investment management industry, and we look forward to his involvement as a Strategic Advisor going forward.”
Mr. Wiesblatt stated: “I am very excited to be joining the Advisory Board at Rockridge. The company has assembled an excellent collection of assets and has built a team with a track record of success. I am looking forward to helping the company navigate through its next phase of growth in a very exciting time for commodity companies and their shareholders.”
About Rockridge Resources Ltd.
Rockridge Resources is a publicly traded mineral exploration company focused on the acquisition, exploration, and development of mineral resource properties in Canada and other mining-friendly jurisdictions. The Company’s Raney Gold Project is a high-grade gold exploration project located in the same greenstone belt that hosts the world-class Timmins and Kirkland Lake lode gold mining camps. The Company's Knife Lake Project is in Saskatchewan, which is ranked as the #3 mining jurisdiction in the world by the Fraser Institute. The project hosts the Knife Lake deposit, which is a VMS, near-surface copper-cobalt-gold-silver-zinc deposit open along strike and at depth. Rockridge’s goal is to maximize shareholder value through new mineral discoveries, committed long-term partnerships, and the advancement of exploration projects in geopolitically favourable jurisdictions.
Additional information about Rockridge Resources and its project portfolio can be found on the Company’s website at www.rockridgeresourcesltd.com. Rockridge currently has 51.1 million shares issued and outstanding.
Rockridge Resources Ltd.
For further information contact myself or:
Jordan Trimble, President or
Spencer Coulter, Corporate Communications
Rockridge Resources Ltd.
Toll Free: 800-567-8181
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.
Forward Looking Information
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Sinch AB (publ): Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management30.11.2020 17:36:35 CET | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Press Release Stockholm, 30 November Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (“Sinch” or the “Company”) has mandated Carnegie and Handelsbanken Capital Markets (together, the “Joint Bookrunners”) to evaluate the conditions for carrying out a directed issue of approximately 3.2 million new shares, through an accelerated book building process (the “Share Issue”). In connection with the Share Issue, and in order to meet the demand, certain larger shareholders, including s
Sinch AB (publ): Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management30.11.2020 17:36:35 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har uppdragit åt Carnegie och Handelsbanken Capital Markets (tillsammans ”Joint Bookrunners”) att utreda förutsättningarna för att genomföra en riktad nyemission om cirka 3,2 miljoner aktier, genom ett accelererat bookbuilding-förfarande (”Nyemissionen”). I samband med Nyemissionen, och i syfte att möta efterfrågan, har vissa s
Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML30.11.2020 16:31:31 CET | Pressemelding
STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS). FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta utvecklingsplanen och ger dessutom möjlighet till påskyndad handläggning av en registreringsansökan. Eprenetapopt (APR-246) är en småmolekylär läke
Karolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML30.11.2020 16:31:31 CET | Press release
STOCKHOLM, SWEDEN – November 30, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS). The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate’s development plan as well as eligibility for accelerated approval and priority review. Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restori
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER30.11.2020 16:20:00 CET | Press release
Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure, 2020-12-02CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the latest maturity date as of 2021-06-02 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2020-11-23 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2020-12-02Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid vol
Olainfarm Group maintains its profit forecast, a short term decline in 9 month sales results30.11.2020 15:59:00 CET | Press release
In 2020, the Olainfarm Group continued its ongoing activity in major sales markets. The highest sales in nine months in 2020 was in Latvia, reaching 28 738 thousand EUR, which is 232 thousand EUR or 1% higher than the same period year ago. Latvia sales represent 32% in Group revenues. Sales in Russia for the nine months period in 2020 amount to 20 590 thousand EUR which is a decrease from 2019 due to extra one-off shipment at the end of 2019 for consumption in the first quarter 2020 amounting to 6 million EUR. “Covid-19 pandemic and restrictions due to it have brought different challenges our way, but we understand how to tackle them, and are committed to reach our growth plans outlined in the company's 5-year strategy. As a long-term investment, we have established a subsidiary in Russia, which allows us to get insights from the medical community and market research so that our efforts are relevant and current to customer needs. I am happy to announce that the new business model in Ru